A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT07258849
This study is recruiting at 9 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Rheumatoid Arthritis (RA)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- June 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Pinnacle Research Group, LLC · Anniston, AL
Arizona · 1
- Arizona Research Center · Phoenix, AZ
Florida · 6
- Clinical Research of West Florida, Inc. (Clearwater) · Clearwater, FL
- GNP Research at Mark Jaffe, MD · Cooper City, FL
- Fortrea Clinical Research Unit · Daytona Beach, FL
- AGA Clinical Trials · Hialeah, FL
- Advanced Pharma CR, LLC · Miami, FL
- Floridian Clinical Research · Miami Lakes, FL
Nevada · 1
- Oasis Clinical Research · Las Vegas, NV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.